RE:RE:Ramping up vtm productionNothing i would consider guidance.
He talked more about drivers.........
Meaningful revenue growth in QAPS, and VTM steady as she goes with Antigens.
He implied proportionate growth in EBITDA by way of margins going into the 60's for both products.
Sounds like Q1 will be meaningfully better than Q1 last year.
But I really didnt get the sense of any guidance that could be put down on paper.
The most meaningful takeawy I got for growth was in QAPS business where they seem poised to sign deals anywhere from the 10's of thousands per month (units) to the 100,000's units per month.
He said each unit is in the $10 range, so that alone incrementally is $100,000 per month incremental in QAPS to $1,000,000 per month in QAPS. He seemed very confident that these deals that were being worked on were more near term in nature.
Anyone else that thinks maybe i didnt quite get this right, let me know.
However, to answer your specific question, I didn't get any sense of guidance other than onward and upward................